Toyama Chemical Co.’s new antibiotic for upper and lower respiratory infections may be approved in Japan as early as September, giving doctors an additional weapon against drug-resistant bacteria.
The Health, Labor and Welfare Ministry may approve the medicine between September and November, Toyama spokesman Yoshinobu Izumi said Monday. Tests on the drug, known by its chemical name garenoxacin, showed it was better able to fight bacteria than other drugs in the same group of antibiotics known as quinolone.
Unable to view this article?
This could be due to a conflict with your ad-blocking or security software.
Please add japantimes.co.jp and piano.io to your list of allowed sites.
We humbly apologize for the inconvenience.